Viewing insider transactions for Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI ) over the last year, we see that insiders were net sellers. This means that a larger number of shares were sold by insiders in relation to shares purchased.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
The Last 12 Months Of Insider Transactions At Intra-Cellular Therapies
In the last twelve months, the biggest single sale by an insider was when the EVP & Chief Commercial Officer, Mark Neumann, sold US$860k worth of shares at a price of US$55.02 per share. So it's clear an insider wanted to take some cash off the table, even below the current price of US$66.32. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. We note that the biggest single sale was only 34% of Mark Neumann's holding. Mark Neumann was the only individual insider to sell shares in the last twelve months.
The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
NasdaqGS:ITCI Insider Trading Volume May 14th 2024
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).
Insider Ownership
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Intra-Cellular Therapies insiders own about US$147m worth of shares (which is 2.1% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
What Might The Insider Transactions At Intra-Cellular Therapies Tell Us?
It doesn't really mean much that no insider has traded Intra-Cellular Therapies shares in the last quarter. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of Intra-Cellular Therapies insider transactions don't fill us with confidence. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Intra-Cellular Therapies. You'd be interested to know, that we found 1 warning sign for Intra-Cellular Therapies and we suggest you have a look.
But note: Intra-Cellular Therapies may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
查看Intra-Cellular Therapies, Inc.(納斯達克股票代碼:ITCI )去年的內部交易,我們發現內部人士是淨賣方。這意味着與購買的股票相比,內部人士出售的股票數量更多。
儘管我們絕不會建議投資者僅根據公司董事的所作所爲做出決定,但邏輯表明,你應該注意內部人士是在買入還是賣出股票。
Intra-Cellular Therapies最近12個月的內部交易
在過去的十二個月中,內部人士最大的一次出售是執行副總裁兼首席商務官馬克·諾伊曼以每股55.02美元的價格出售了價值86萬美元的股票。因此,很明顯,一位內部人士想從桌上提取一些現金,甚至低於目前的66.32美元。通常,當內部人士以低於當前價格的價格出售時,我們認爲這令人沮喪,因爲這表明他們對較低的估值感到滿意。但是,儘管內部銷售有時令人沮喪,但這只是一個微弱的信號。我們注意到,最大的單筆銷售僅佔馬克·諾伊曼持股量的34%。馬克·諾伊曼是過去十二個月中唯一出售股票的內部人士。
下圖顯示了去年的內部交易(公司和個人)。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!
納斯達克GS:ITCI 內部交易量 2024 年 5 月 14 日
如果你喜歡買內部人士買入而不是賣出的股票,那麼你可能會喜歡這份免費的公司名單。(提示:業內人士一直在購買它們)。
內部所有權
測試公司領導者與其他股東之間一致性的另一種方法是查看他們擁有多少股份。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。細胞內療法內部人士擁有價值約1.47億美元的股份(佔該公司的2.1%)。內部人士的這種重要所有權通常會增加公司爲所有股東的利益而經營的機會。
Intra-Cellular Therapies的內部交易可能告訴我們什麼?
上個季度沒有內部人士交易過Intra-Cellular Therapies的股票,這並沒有多大意義。內部人士擁有大量股票令人鼓舞,但我們希望看到更多的內幕買盤,因爲去年的細胞內幕交易並沒有使我們充滿信心。除了了解正在進行的內幕交易外,確定細胞內療法面臨的風險也是有益的。你可能會有興趣知道,我們發現了一個細胞內療法的警告信號,我們建議你看看。
但請注意:Intra-Cellular Therapies可能不是最好的買入股票。因此,來看看這份投資回報率高、債務低的有趣公司的免費清單。
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。